

# Long-Acting Risperidone and Oral Antipsychotics in Un

New England Journal of Medicine

364, 842-851

DOI: [10.1056/nejmoa1005987](https://doi.org/10.1056/nejmoa1005987)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Corifollitropin alfa: a new recombinant FSH gonadotropin analog. <i>Expert Review of Obstetrics and Gynecology</i> , 2011, 6, 395-402.	0.4	2
2	The place of observational studies in assessing the effectiveness of depot antipsychotics. <i>Schizophrenia Research</i> , 2011, 131, 260-261.	1.1	21
3	Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. <i>Patient Preference and Adherence</i> , 2011, 5, 601.	0.8	4
5	Recent advances in pharmacological treatment of psychosis in late life. <i>Current Opinion in Psychiatry</i> , 2011, 24, 455-460.	3.1	8
6	The Pharmacoepidemiology of Antipsychotics for Adults with Schizophrenia in Canada, 2005 to 2009. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 630-634.	0.9	9
7	Long-Acting Risperidone and Oral Antipsychotics in Schizophrenia. <i>New England Journal of Medicine</i> , 2011, 364, 2264-2266.	13.9	1
8	Increased use of antipsychotic long-acting injections with community treatment orders. <i>Therapeutic Advances in Psychopharmacology</i> , 2011, 1, 37-45.	1.2	26
9	Schizophrenia guidelines across the world: A selective review and comparison. <i>International Review of Psychiatry</i> , 2011, 23, 379-387.	1.4	56
10	Second-generation long-acting injectable antipsychotic agents: an overview. <i>Drug and Therapeutics Bulletin</i> , 2012, 50, 102-105.	0.3	5
11	Adherence and Long-Acting Injectable Antipsychotics in Schizophrenia: An Update. <i>Dusunen Adam</i> , 2012, , .	0.0	1
13	Rethinking the role of long-acting atypical antipsychotics in the community setting. <i>International Clinical Psychopharmacology</i> , 2012, 27, 1.	0.9	27
14	Prevalence of Concomitant Oral Antipsychotic Drug Use Among Patients Treated With Long-Acting, Intramuscular, Antipsychotic Medications. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 323-328.	0.7	39
15	The Effect of Race-Ethnicity and Geography on Adoption of Innovations in the Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2012, 63, 1171-1177.	1.1	9
16	Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1631-1643.	0.9	1
17	The Potential Role of Long-Acting Injectable Antipsychotics in People With Schizophrenia and Comorbid Substance Use. <i>Journal of Dual Diagnosis</i> , 2012, 8, 50-61.	0.7	24
18	Applying Motivational Interviewing to the initiation of long-acting injectable atypical antipsychotics. <i>Australasian Psychiatry</i> , 2012, 20, 138-142.	0.4	11
19	The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria. <i>Therapeutic Advances in Psychopharmacology</i> , 2012, 2, 169-177.	1.2	16
20	Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-3.	0.7	18

#	ARTICLE	IF	CITATIONS
21	Long-Acting Injectable Antipsychotic Medications in Patients With Comorbid Schizophrenia and Substance Use Disorders. <i>Journal of Dual Diagnosis</i> , 2012, 8, 62-63.	0.7	2
22	Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-12.	0.7	67
23	Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-8.	0.7	42
24	Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 696-702.	1.1	18
25	Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia. <i>Yearbook of Psychiatry and Applied Mental Health</i> , 2012, 2012, 377-378.	0.1	0
26	Optimizing Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment. <i>CNS Spectrums</i> , 2012, 17, 10-21.	0.7	14
27	Antipsychotic Medication Nonadherence: Risk Factors and Remedies. <i>Focus (American Psychiatric Association)</i> , 2012, 10, 10-15.	0.4	5
30	Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2012, 436, 798-805.	2.6	95
31	Déterminer les tendances et les transitions dans la prise en charge de patients atteints de schizophrénie aux consultations externes des hôpitaux. <i>Healthcare Management Forum</i> , 2012, 25, S65-S70.	0.6	0
32	Patients' acceptance of the deltoid application of risperidone long-acting injection. <i>European Neuropsychopharmacology</i> , 2012, 22, 897-901.	0.3	7
33	Identifying Trends and Transitions in the Hospital Outpatient Management of Patients with Schizophrenia. <i>Healthcare Management Forum</i> , 2012, 25, S59-S64.	0.6	0
35	Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. <i>Psychiatry Research</i> , 2012, 197, 1-6.	1.7	148
36	Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 245-250.	2.5	16
37	Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model. <i>Annals of General Psychiatry</i> , 2012, 11, 29.	1.2	5
38	Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). <i>Schizophrenia Research</i> , 2012, 134, 187-194.	1.1	87
39	Clinical and psychosocial remission in schizophrenia: correlations with antipsychotic treatment. <i>BMC Psychiatry</i> , 2012, 12, 108.	1.1	21
40	Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 617-624.	1.1	324
41	Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. <i>Patient Preference and Adherence</i> , 2012, 6, 533.	0.8	10

#	ARTICLE	IF	CITATIONS
42	Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. <i>International Journal of General Medicine</i> , 2012, 5, 391.	0.8	10
43	Solid lipid nanoparticles (SLN) - based hydrogels as potential carriers for oral transmucosal delivery of Risperidone: Preparation and characterization studies. <i>Colloids and Surfaces B: Biointerfaces</i> , 2012, 93, 241-248.	2.5	79
44	Veteran Subjects Willingness to Participate in Schizophrenia Clinical Trials. <i>Psychiatric Quarterly</i> , 2013, 84, 209-218.	1.1	1
45	Polypharmacy in Psychiatry Practice, Volume II. , 2013, , .		2
46	Healthcare Cost Reductions Associated with the Use of LAI Formulations of Antipsychotic Medications Versus Oral Among Patients with Schizophrenia. <i>Journal of Behavioral Health Services and Research</i> , 2013, 40, 355-366.	0.6	44
47	Long-Acting Injectable Aripiprazole. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, 7, 87-92.	1.4	19
48	Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. <i>Journal of Clinical Epidemiology</i> , 2013, 66, S37-S41.	2.4	109
49	Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures. <i>Psychiatry Research</i> , 2013, 209, 291-296.	1.7	14
51	Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective. <i>CNS Drugs</i> , 2013, 27, 637-652.	2.7	61
52	Improving Treatment Adherence in Your Patients with Schizophrenia. <i>Clinical Drug Investigation</i> , 2013, 33, 97-107.	1.1	38
53	Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes. <i>British Journal of Psychiatry</i> , 2013, 203, 215-220.	1.7	12
54	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 2-44.	1.3	343
55	Antipsychotic Formulation and One-Year Rehospitalization of Schizophrenia Patients: A Population-Based Cohort Study. <i>Psychiatric Services</i> , 2013, 64, 1259-1262.	1.1	15
56	Efficacy and safety of second-generation long-acting injections in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2013, 28, 57-66.	0.9	83
57	Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia. <i>Evidence-Based Mental Health</i> , 2013, 16, 19-19.	2.2	0
58	Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 624-630.	1.3	53
59	The Psychopharmacology Algorithm Project at the Harvard South Shore Program. <i>Harvard Review of Psychiatry</i> , 2013, 21, 18-40.	0.9	38
60	Adverse Effects Associated with Second-Generation Antipsychotic Long-Acting Injection Treatment: A Comprehensive Systematic Review. <i>Pharmacotherapy</i> , 2013, 33, 1087-1106.	1.2	36

#	ARTICLE	IF	CITATIONS
61	Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. <i>World Psychiatry</i> , 2013, 12, 216-226.	4.8	356
62	Progress in compliance research and intervention: a commentary. <i>World Psychiatry</i> , 2013, 12, 227-229.	4.8	1
63	Naturalistic outcomes of community treatment orders: antipsychotic long-acting injections versus oral medication. <i>Journal of Psychopharmacology</i> , 2013, 27, 629-637.	2.0	16
64	Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 5-13.	0.9	47
65	Why Are Canadians Complacent about Long-Acting Injectable Antipsychotic Therapies? Come on, Canada, You Can Do Better!. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 3-4.	0.9	2
66	Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. <i>Patient Preference and Adherence</i> , 2013, 7, 1171.	0.8	137
67	Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 341.	1.0	23
68	Tackling nonadherence in psychiatric disorders: current opinion. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1069.	1.0	48
69	Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders. <i>Current Addiction Reports</i> , 2014, 1, 251-260.	1.6	18
70	A review on schizophrenia and relapse—a quest for user-friendly psychopharmacotherapy. <i>Human Psychopharmacology</i> , 2014, 29, 414-426.	0.7	29
71	Video Conferencing Technology in Research on Schizophrenia: A Qualitative Study of Site Research Staff. <i>Psychiatry (New York)</i> , 2014, 77, 98-102.	0.3	8
72	Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 322-331.	0.9	25
73	Long-acting paliperidone palmitate — interim results of an observational study of its effect on hospitalization. <i>International Clinical Psychopharmacology</i> , 2014, 29, 229-234.	0.9	45
74	Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 426-434.	0.7	30
75	Antipsychotic Medications for Schizophrenia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1468.	3.8	1
76	Maintenance Treatment With Long-Acting Injectable Antipsychotics. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1973.	3.8	6
77	Effectiveness of Paliperidone Palmitate vs Haloperidol Decanoate for Maintenance Treatment of Schizophrenia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1978.	3.8	129
78	Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. <i>Schizophrenia Bulletin</i> , 2014, 40, 192-213.	2.3	332

#	ARTICLE	IF	CITATIONS
79	Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary. <i>Schizophrenia Research</i> , 2014, 152, 246-254.	1.1	59
80	Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). <i>World Journal of Biological Psychiatry</i> , 2014, 15, 534-545.	1.3	18
81	Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1029-1042.	0.9	6
82	Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. <i>British Journal of Psychiatry</i> , 2014, 205, 135-144.	1.7	130
83	Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. <i>Psychiatry and Clinical Neurosciences</i> , 2014, 68, 37-49.	1.0	74
84	Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. <i>Current Medical Research and Opinion</i> , 2014, 30, 1643-1655.	0.9	47
85	Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?. <i>Drug and Alcohol Dependence</i> , 2014, 140, 118-122.	1.6	38
86	Ethics Commentary: Ethics in Psychopharmacology Practice. <i>Focus (American Psychiatric Publishing)</i> , 2014, 12, 178-183.	0.4	1
87	Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases. <i>International Journal of Clinical Practice</i> , 2014, 68, 1514-1522.	0.8	18
88	Long-acting injectable antipsychotics: shall the last be first?. <i>CNS Spectrums</i> , 2014, 19, 3-5.	0.7	66
89	Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 67-74.	0.9	26
90	Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study. <i>Psychiatry and Clinical Neurosciences</i> , 2015, 69, 497-503.	1.0	9
91	Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2015, 30, 272-281.	0.9	25
92	The reduction of volume and fiber bundle connections in the hippocampus of EGR3 transgenic schizophrenia rats. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1625.	1.0	5
93	Treatment of Schizophrenia: Past, Present and Future. <i>Journal of Microbiology and Biotechnology</i> , 2015, 25, 95-99.	0.9	1
94	A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates. <i>International Clinical Psychopharmacology</i> , 2015, 30, 230-236.	0.9	30
95	Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. <i>Schizophrenia Research</i> , 2015, 169, 393-399.	1.1	115
96	Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 89-99.	0.6	11

#	ARTICLE	IF	CITATIONS
97	Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2015, 10, 219-246.	1.0	11
98	Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 822.	6.0	205
99	Quantifying motivational deficits and apathy: A review of the literature. <i>European Neuropsychopharmacology</i> , 2015, 25, 1060-1081.	0.3	22
100	Effectiveness of long-acting injectable antipsychotics: a clinical perspective: Table A1. <i>Evidence-Based Mental Health</i> , 2015, 18, 36-39.	2.2	25
101	Antipsychotic medication in schizophrenia: a review. <i>British Medical Bulletin</i> , 2015, 114, 169-179.	2.7	356
102	Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics. <i>International Clinical Psychopharmacology</i> , 2015, 30, 151-157.	0.9	18
103	Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. <i>CNS Drugs</i> , 2015, 29, 773-799.	2.7	131
104	A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophreniaâ€”A nationwide study. <i>Schizophrenia Research</i> , 2015, 169, 400-405.	1.1	15
105	Why are long-acting injectable antipsychotics still underused?. <i>BJ Psych Advances</i> , 2015, 21, 98-105.	0.5	17
106	The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics. <i>CNS Drugs</i> , 2015, 29, 637-658.	2.7	69
107	The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 969-981.	1.4	9
108	Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?. <i>Therapeutic Advances in Psychopharmacology</i> , 2015, 5, 278-288.	1.2	16
109	The impact of missing data on the results of a schizophrenia study. <i>Pharmaceutical Statistics</i> , 2015, 14, 4-10.	0.7	4
110	Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 449-459.	2.3	65
111	Post-Injection Delirium/Sedation Syndrome in Patients Treated with Olanzapine Pamoate: Mechanism, Incidence, and Management. <i>CNS Drugs</i> , 2015, 29, 41-46.	2.7	30
112	Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia â€” A 3-year follow-up. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 539-545.	0.8	13
113	An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016, 9, 198-208.	1.4	18
115	The Benefits of Antipsychotic Drugs. , 2016, , 295-309.		4

#	ARTICLE	IF	CITATIONS
116	Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 917.	1.0	25
117	Antipsychotic long-acting injections: A community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation. <i>Schizophrenia Research</i> , 2016, 178, 58-63.	1.1	25
118	Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. <i>Psychiatric Services</i> , 2016, 67, 1370-1372.	1.1	8
120	Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics. <i>Psychiatric Services</i> , 2016, 67, 1183-1188.	1.1	24
121	The role of long-acting injection in schizophrenia treatment and future challenges. <i>Drug Delivery System</i> , 2016, 31, 186-193.	0.0	0
122	Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. <i>CNS Drugs</i> , 2016, 30, 689-701.	2.7	67
123	Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2016, 67, 1124-1130.	1.1	13
124	A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD). <i>Journal of Psychiatric Research</i> , 2016, 80, 87-92.	1.5	11
125	Risperidone (depot) for schizophrenia. <i>The Cochrane Library</i> , 2016, 4, CD004161.	1.5	16
126	Pharmacological treatment of schizophrenia with comorbid substance use disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 231-253.	0.9	16
127	Comparison of treatment effectiveness and medical costs for different long-acting injectable antipsychotics in patients with schizophrenia in Taiwan: A nationwide population-based cohort study. <i>Schizophrenia Research</i> , 2016, 173, 37-44.	1.1	9
128	Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials. <i>General Hospital Psychiatry</i> , 2016, 39, 46-52.	1.2	79
129	The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. <i>Current Treatment Options in Psychiatry</i> , 2017, 4, 117-126.	0.7	50
130	Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 429-438.	2.2	23
131	Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. <i>Psychiatry Research</i> , 2017, 247, 257-264.	1.7	32
133	CNS Drug Delivery for Diseases Eradication: An Overview. , 2017, , 157-185.		0
134	Guidelines for the Pharmacotherapy of Schizophrenia in Adults. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 604-616.	0.9	212
135	Risperidone mucoadhesive buccal tablets: formulation design, optimization and evaluation. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3355-3365.	2.0	36



#	ARTICLE	IF	CITATIONS
136	Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone. <i>International Clinical Psychopharmacology</i> , 2018, 33, 204-212.	0.9	4
137	Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. <i>New England Journal of Medicine</i> , 2018, 378, 507-517.	13.9	238
139	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. <i>Schizophrenia Bulletin</i> , 2018, 44, 603-619.	2.3	137
140	Management of Post-Traumatic Nightmares: a Review of Pharmacologic and Nonpharmacologic Treatments Since 2013. <i>Current Psychiatry Reports</i> , 2018, 20, 108.	2.1	35
141	Antipsychotic prescription patterns and treatment costs of schizophrenia in northwestern Pakistan: A one-year observational study. <i>Tropical Journal of Pharmaceutical Research</i> , 2018, 17, 339.	0.2	2
142	Psychotic Disorders. <i>New England Journal of Medicine</i> , 2018, 379, 270-280.	13.9	161
143	Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 205-211.	1.0	15
144	Discontinuation rates during long-term, second-generation antipsychotic long-acting injection treatment: A systematic review. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 216-230.	1.0	14
145	Recovery-Oriented Outcomes Associated with Long-Acting Injectable Antipsychotics in an Urban Safety-Net Population. <i>Community Mental Health Journal</i> , 2019, 55, 979-982.	1.1	7
146	Differences in the Effectiveness of Long-Acting Injection and Orally Administered Antipsychotics in Reducing Rehospitalization among Patients with Schizophrenia Receiving Home Care Services. <i>Journal of Clinical Medicine</i> , 2019, 8, 823.	1.0	5
147	The Long-Acting Injectable Antipsychotics in Clinical Practice. <i>Journal of Korean Neuropsychiatric Association</i> , 2019, 58, 29.	0.2	1
148	Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 509-527.	1.3	20
149	Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres. <i>PLoS ONE</i> , 2019, 14, e0211938.	1.1	3
150	Long-Acting Injectables Versus Oral Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 441-445.	0.7	15
151	Attitudes Toward Long-Term Medication Use—A Comparison Between Concerned Populations and a Sample From the German General Population. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 357-361.	0.7	1
152	Insight and medication adherence in schizophrenia: An analysis of the CATIE trial. <i>Neuropharmacology</i> , 2020, 168, 107634.	2.0	48
153	Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder. <i>Microbial Biotechnology</i> , 2020, 14, 69-79.	0.9	24
154	Pill or needle? Determinants of the preference for long-acting injection over oral treatment in people facing chronic illness. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 98, 109798.	2.5	0

#	ARTICLE	IF	CITATIONS
155	Pharmacoevidence research: delivering evidence about drug safety and effectiveness in mental health. <i>Lancet Psychiatry</i> , 2020, 7, 363-370.	3.7	23
156	Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. <i>CNS Spectrums</i> , 2021, 26, 338-344.	0.7	28
157	Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. <i>International Clinical Psychopharmacology</i> , 2020, 35, 221-228.	0.9	15
158	Attitudes of European physicians towards the use of long-acting injectable antipsychotics. <i>BMC Psychiatry</i> , 2020, 20, 123.	1.1	17
159	The effectiveness of long-acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia. <i>Human Psychopharmacology</i> , 2020, 35, e2729.	0.7	8
160	Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring. <i>Scientific Reports</i> , 2020, 10, 1219.	1.6	2
161	Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia. <i>Annals of General Psychiatry</i> , 2020, 19, 1.	1.2	37
162	Multiple antipsychotics use in patients with schizophrenia: Why do we use it, what are the results from patient follow-ups?. <i>Asian Journal of Psychiatry</i> , 2020, 52, 102063.	0.9	5
163	A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. <i>Schizophrenia Research</i> , 2020, 220, 92-97.	1.1	2
164	Risk of withdrawal of consent for treatment with long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled trials. <i>Schizophrenia Research</i> , 2021, 229, 94-101.	1.1	2
165	Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity. <i>Behavioural Brain Research</i> , 2021, 403, 113126.	1.2	10
166	Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. <i>Lancet Psychiatry</i> , 2021, 8, 387-404.	3.7	160
167	Need for Ethnic and Population Diversity in Psychosis Research. <i>Schizophrenia Bulletin</i> , 2021, 47, 889-895.	2.3	25
168	Differentiation in Neurological Soft Sign Scores on Schizophrenic Patients with Antipsychotic Treatment. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2021, 9, 249-253.	0.1	0
169	Comparing the reporting and conduct quality of exercise and pharmacological randomised controlled trials: a systematic review. <i>BMJ Open</i> , 2021, 11, e048218.	0.8	9
170	Japanese Society of Neuropsychopharmacology: Guideline for Pharmacological Therapy of Schizophrenia. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 266-324.	1.1	48
171	Schizophrenia Spectrum and Other Psychotic Disorders. , 2021, , .		0
173	Pharmacological Strategies to Enhance Adherence in Schizophrenia. , 2014, , 85-97.		2

#	ARTICLE	IF	CITATIONS
174	Current Progresses on Nanodelivery Systems for the Treatment of Neuropsychiatric Diseases: Alzheimer's and Schizophrenia. <i>Current Pharmaceutical Design</i> , 2013, 19, 7185-7195.	0.9	31
175	Assessing the Population Impact of Published Intervention Studies. <i>NAM Perspectives</i> , 2015, 5, .	1.3	1
176	Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. <i>Dialogues in Clinical Neuroscience</i> , 2011, 13, 155-172.	1.8	38
177	Long-Acting Injectable Antipsychotics and the Management of Nonadherence. <i>Psychiatric Annals</i> , 2011, 41, 271-278.	0.1	7
178	Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 669-675.	1.1	46
179	Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. <i>Drugs in Context</i> , 2015, 4, 1-12.	1.0	15
180	Are Depot Anti-psychotics Associated with Longer Persistence in Treatment Compared with Oral Antipsychotics among Patients with Schizophrenia?. <i>Journal of Pharmaceutical Research International</i> , 2017, 18, 1-8.	1.0	1
181	Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics. <i>Mental Health Clinician</i> , 2016, 6, 248-253.	0.5	7
182	Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis. <i>Mental Health Clinician</i> , 2018, 8, 56-62.	0.5	28
185	Antipsychotic Polypharmacy in Schizophrenia. How to Counteract This Common Practice?. , 2013, , 81-107.		0
187	Hospitalizations and emergency room visits after initiation of long-acting injectable antipsychotics. <i>Mental Health Clinician</i> , 2016, 6, 134-141.	0.5	1
188	Correlation between telomere length and efficacy of oral and long-acting injectable antipsychotics on severity and cognitive impairment of schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 157-164.	1.2	0
190	Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety. <i>Psychopharmacology Bulletin</i> , 2017, 47, 42-52.	0.0	22
191	Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?. <i>Psychopharmacology Bulletin</i> , 2018, 48, 8-15.	0.0	0
192	Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis. <i>Psychopharmacology Bulletin</i> , 2018, 48, 25-61.	0.0	9
193	Risk factors associated with readmissions of patients with severe mental disorders under treatment with antipsychotics. <i>BMC Psychiatry</i> , 2022, 22, 189.	1.1	5
194	The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta-analysis. <i>International Journal of Mental Health Nursing</i> , 2022, 31, 469-535.	2.1	7
195	Sexual Dysfunction in Schizophrenia: A Narrative Review of the Mechanisms and Clinical Considerations. <i>Psychiatry International</i> , 2022, 3, 29-42.	0.5	4

#	ARTICLE	IF	CITATIONS
196	Formulation and optimization of Paliperidone palmitate biodegradable injectable microspheres using Box-Behnken design. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 74, 103609.	1.4	1
197	Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia. <i>Current Medical Research and Opinion</i> , 2022, 38, 1621-1630.	0.9	2
198	Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia. <i>JAMA Network Open</i> , 2022, 5, e2224163.	2.8	8
199	A Literature Review on the Efficacy of Injectable Neuroleptics in the Treatment of Schizophrenia. , 2022, 6, 1-6.		0
200	Comparison of prolactin level, sexual function, body mass index, and liver function tests in patients using depot antipsychotics. <i>Cukurova Medical Journal</i> , 2022, 47, 1172-1178.	0.1	0
201	A Qualitative Scoping Review of Early-Terminated Clinical Trials Sponsored by the Department of Veterans Affairs Cooperative Studies Program From 2010 to 2020. <i>Epidemiologic Reviews</i> , 2022, 44, 110-120.	1.3	3
202	Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration. <i>Trials</i> , 2023, 24, .	0.7	0
203	Impact of Multi-site Clinical Trial Results on Clinical Practice: Use of Risperidone to Treat PTSD Nationally in the Veterans Health Administration. <i>Psychiatry Research</i> , 2023, 321, 115071.	1.7	0